An Italian expert consensus on the management of alpha1-antitrypsin deficiency: a comprehensive set of algorithms.


Journal

Panminerva medica
ISSN: 1827-1898
Titre abrégé: Panminerva Med
Pays: Italy
ID NLM: 0421110

Informations de publication

Date de publication:
Jun 2022
Historique:
pubmed: 12 2 2022
medline: 14 7 2022
entrez: 11 2 2022
Statut: ppublish

Résumé

Alpha<inf>1</inf>-antitrypsin deficiency (AATD) is a genetic-based risk condition, mainly affecting the lungs and liver. Despite its wide distribution, it is largely underdiagnosed, thus being considered a rare disease, and is consequently managed in ad-hoc reference centers. Unfortunately, an easy-to-use algorithm for managing such a complex disease is still lacking. An expert consensus meeting was conducted among experts in the management of AATD to build a comprehensive algorithm, including diagnosis, monitoring, AAT therapy, rehabilitation and lung transplantation, and liver disease, that could serve as a guide for physicians and treating centers. A panel of AATD specialists evaluated the results of their work. Diagnosis is the most delicate phase, and awareness about this condition should be raised among GPs. A set of recommendations has been written about the most suitable follow-up visits. Augmentation therapy with AAT may be useful to reduce the progression of emphysema and lung function decline in selected patients. Exercise capacity may be improved by pulmonary rehabilitation and, in selected cases, by lung volume reduction or lung transplantation. Support therapies are needed for those who develop liver disease, and, in selected cases, liver transplantation may be considered. Patients should be carefully educated about their lifestyle, including smoking cessation, body weight control, and reduced alcohol intake. The proposed algorithm obtained the endorsement of the Italian Society of Pneumology (SIP). However, further studies and additional clinical data are required to confirm the validity of these recommendations.

Sections du résumé

BACKGROUND BACKGROUND
Alpha<inf>1</inf>-antitrypsin deficiency (AATD) is a genetic-based risk condition, mainly affecting the lungs and liver. Despite its wide distribution, it is largely underdiagnosed, thus being considered a rare disease, and is consequently managed in ad-hoc reference centers. Unfortunately, an easy-to-use algorithm for managing such a complex disease is still lacking.
METHODS METHODS
An expert consensus meeting was conducted among experts in the management of AATD to build a comprehensive algorithm, including diagnosis, monitoring, AAT therapy, rehabilitation and lung transplantation, and liver disease, that could serve as a guide for physicians and treating centers. A panel of AATD specialists evaluated the results of their work.
RESULTS RESULTS
Diagnosis is the most delicate phase, and awareness about this condition should be raised among GPs. A set of recommendations has been written about the most suitable follow-up visits. Augmentation therapy with AAT may be useful to reduce the progression of emphysema and lung function decline in selected patients. Exercise capacity may be improved by pulmonary rehabilitation and, in selected cases, by lung volume reduction or lung transplantation. Support therapies are needed for those who develop liver disease, and, in selected cases, liver transplantation may be considered. Patients should be carefully educated about their lifestyle, including smoking cessation, body weight control, and reduced alcohol intake.
CONCLUSIONS CONCLUSIONS
The proposed algorithm obtained the endorsement of the Italian Society of Pneumology (SIP). However, further studies and additional clinical data are required to confirm the validity of these recommendations.

Identifiants

pubmed: 35146988
pii: S0031-0808.22.04592-X
doi: 10.23736/S0031-0808.22.04592-X
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

215-227

Investigateurs

Bruno Balbi (B)
Federica Benini (F)
Luciano Corda (L)
Angelo Corsico (A)
Ilaria Ferrarotti (I)
Nuccia Gatta (N)
Anna Annunziata (A)
Elena Bargagli (E)
Francesco Blasi (F)
Marc Miravitlles (M)
Alessandro Sanduzzi Zamparelli (A)
Mario Torrazza (M)
Andrea Vianello (A)

Auteurs

Bruno Balbi (B)

Section of Pulmonary Rehabilitation, Institute of Veruno, Istituti Clinici Scientifici Maugeri IRCCS, Novara, Italy - bruno.balbi@icsmaugeri.it.

Federica Benini (F)

Center for the Diagnosis, Monitoring and Therapy of Alpha1-Antitrypsin Deficiency, Gastroenterology Unit, Department of Medicine, Spedali Civili, Brescia, Italy.

Luciano Corda (L)

Center for Diagnosis, Monitoring and Therapy of Alpha1-Antitrypsin Deficiency, Respiratory Medicine Unit, Department of Internal Medicine, Spedali Civili, Brescia, Italy.

Angelo Corsico (A)

Center for the Diagnosis of Alpha1-Antitrypsin Hereditary Deficiency, Chest Medicine Unit, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.

Ilaria Ferrarotti (I)

Center for the Diagnosis of Alpha1-Antitrypsin Hereditary Deficiency, Chest Medicine Unit, IRCCS Policlinico San Matteo Foundation, University of Pavia, Pavia, Italy.

Nuccia Gatta (N)

Associazione Nazionale Alfa1-At per la tutela dei pazienti con Deficit di Alfa1-Antitripsina, Sarezzo, Brescia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH